NanoLogix, Inc. Company  Overview in Brief

NanoLogix is an industry innovator in the research, development, and commercialization of nano-biotechnologies, applications and processes.  The Company has developed and owns, or has rights to several patents related to various medical technologies.  Five of them also have Hydrogen generation aspects. 

In the past year the Company has filed numerous patent applications for discoveries related to Hydrogen bioreactors, medical testing and our ultra fast BioNanoChannel(TM) bacteria identification technology. NanoLogix is presently operating a Hydrogen bioreactor at Welch's Food and has signed an agreement with the City of Erie Wastewater Treatment Plant for a prototype bioreactor installation.

These patents are already generating royalty revenues from licensee Nutra Pharma (NPHC.ob). The company also owns a patent for the non-toxic induction of apoptosis ('cell suicide') for the treatment of cancer.

In addition, the Company has also filed patent applications for discoveries related to medical testing and  Rapid BioNanoChannel(TM) Microorganism Diagnostics Technology.

To see a list of NanoLogix' new BioNanoChannel™ products please choose from the list below.

Please make a selection: BNP Membrane BioNanoChannel BNC-1 BNC-Ab BNP-1 BNF-1 BNF-2 GP-2ML Plate BNC-Mg Device BNC/BNP Manifold

Please contact us for more information.

 

» Press Release Archive

» Management Team

» NanoLogix Financials

» In the Media

» News Videos About NNLX

» Information Requests